| Date Filed | Type | Description |
| 10/12/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 10/10/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 10/02/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 08/21/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/10/2023 |
SC 13G
| INTRACOASTAL CAPITAL, LLC reports a 7.6% stake in Adamis Pharmaceuticals Corporation |
| 08/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 08/03/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/27/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 07/26/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/15/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 06/12/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/05/2023 |
SC 13D
| Versi Group LLC reports a 10% stake in Adamis Pharmaceuticals Corporation |
| 05/30/2023 |
4
| Versi Ebrahim (CEO) has filed a Form 4 on Adamis Pharmaceuticals Corp|
Txns:
| Granted 8,745 shares
@ $0
Granted 177,194 shares
@ $0
Granted 20,577 options to buy
@ $2.9, valued at
$59.7k
Granted 1,941 convertible preferred
@ $0 |
|
| 05/30/2023 |
4
| Desai Meera J. (Director) has filed a Form 4 on Adamis Pharmaceuticals Corp|
Txns:
| Granted 3,138 shares
@ $0 |
|
| 05/30/2023 |
4
| Versi Jannine (Director) has filed a Form 4 on Adamis Pharmaceuticals Corp|
Txns:
| Granted 177,194 shares
@ $0
Granted 5,144 options to buy
@ $2.9, valued at
$14.9k
Granted 1,941 convertible preferred
@ $0 |
|
| 05/30/2023 |
3
| Versi Jannine (Director) has filed a Form 3 on Adamis Pharmaceuticals Corp |
| 05/30/2023 |
3
| Versi Ebrahim (CEO) has filed a Form 3 on Adamis Pharmaceuticals Corp |
| 05/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...|
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock",
"Letter dated May 24, 2023, between the Company and David J. Marguglio",
"Offer letter dated May 24, 2023, between the Company and Ebrahim Versi, M.D., Ph.D",
"DMK 2016 Stock Plan",
"SAN DIEGO, May 25, 2023 – Adamis Pharmaceuticals Corporation" |
|
| 05/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
|